168 related articles for article (PubMed ID: 10537294)
41. Antitumor efficacy of combination chemotherapy with UFT and cyclophosphamide against human breast cancer xenografts in nude mice.
Haga S; Shimizu T; Imamura H; Watanabe O; Kinoshita J; Fukushima M; Kajiwara T
Anticancer Res; 1999; 19(3A):1791-6. PubMed ID: 10470117
[TBL] [Abstract][Full Text] [Related]
42. Antitumor efficacy of TRA-8 anti-DR5 monoclonal antibody alone or in combination with chemotherapy and/or radiation therapy in a human breast cancer model.
Buchsbaum DJ; Zhou T; Grizzle WE; Oliver PG; Hammond CJ; Zhang S; Carpenter M; LoBuglio AF
Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3731-41. PubMed ID: 14506165
[TBL] [Abstract][Full Text] [Related]
43. Synergistic anti-tumor activity of a novel immunomodulator, BCH-1393, in combination with cyclophosphamide.
Kadhim S; Penney C; Lagraoui M; Heibein J; Attardo G; Zacharie B; Connolly T; Gagnon L
Int J Immunopharmacol; 2000 Sep; 22(9):659-71. PubMed ID: 10884587
[TBL] [Abstract][Full Text] [Related]
44. Effects of a pure antiestrogen on apoptosis and proliferation within human breast ductal carcinoma in situ.
Gandhi A; Holland PA; Knox WF; Potten CS; Bundred NJ
Cancer Res; 2000 Aug; 60(15):4284-8. PubMed ID: 10945643
[TBL] [Abstract][Full Text] [Related]
45. Synergistic interaction between tirapazamine and cyclophosphamide in human breast cancer xenografts.
Langmuir VK; Rooker JA; Osen M; Mendonca HL; Laderoute KR
Cancer Res; 1994 Jun; 54(11):2845-7. PubMed ID: 8187065
[TBL] [Abstract][Full Text] [Related]
46. In vitro and in vivo biologic evaluation of long-circulating biodegradable drug carriers loaded with the pure antiestrogen RU 58668.
Ameller T; Marsaud V; Legrand P; Gref R; Renoir JM
Int J Cancer; 2003 Sep; 106(3):446-54. PubMed ID: 12845687
[TBL] [Abstract][Full Text] [Related]
47. Preclinical studies with toremifene as an antitumor agent.
Robinson SP; Parker CJ; Jordan VC
Breast Cancer Res Treat; 1990 Aug; 16 Suppl():S9-17. PubMed ID: 2149286
[TBL] [Abstract][Full Text] [Related]
48. Endocrine and antitumor effects of combined treatment with an antiprogestin and antiestrogen or luteinizing hormone-releasing hormone agonist in female rats bearing mammary tumors.
Bakker GH; Setyono-Han B; Portengen H; De Jong FH; Foekens JA; Klijn JG
Endocrinology; 1989 Sep; 125(3):1593-8. PubMed ID: 2527151
[TBL] [Abstract][Full Text] [Related]
49. Antitumor activity of cryptophycins: effect of infusion time and combination studies.
Menon K; Alvarez E; Forler P; Phares V; Amsrud T; Shih C; Al-Awar R; Teicher BA
Cancer Chemother Pharmacol; 2000; 46(2):142-9. PubMed ID: 10972484
[TBL] [Abstract][Full Text] [Related]
50. Cross-resistance of triphenylethylene-type antiestrogens but not ICI 182,780 in tamoxifen-stimulated breast tumors grown in athymic mice.
Lee ES; Schafer JM; Yao K; England G; O'Regan RM; De Los Reyes A; Jordan VC
Clin Cancer Res; 2000 Dec; 6(12):4893-9. PubMed ID: 11156249
[TBL] [Abstract][Full Text] [Related]
51. Additive antitumor effect of aromatase inhibitor letrozole and antiestrogen fulvestrant in a postmenopausal breast cancer model.
Jelovac D; Macedo L; Goloubeva OG; Handratta V; Brodie AM
Cancer Res; 2005 Jun; 65(12):5439-44. PubMed ID: 15958593
[TBL] [Abstract][Full Text] [Related]
52. Effects of endocrine regulation of growth of a mouse mammary tumor on its sensitivity to chemotherapy.
Emerman JT; Siemiatkowski J
Cancer Res; 1984 Apr; 44(4):1327-32. PubMed ID: 6704951
[TBL] [Abstract][Full Text] [Related]
53. Flaxseed and soy protein isolate, alone and in combination, differ in their effect on bone mass, biomechanical strength, and uterus in ovariectomized nude mice with MCF-7 human breast tumor xenografts.
Power KA; Ward WE; Chen JM; Saarinen NM; Thompson LU
J Toxicol Environ Health A; 2007 Nov; 70(22):1888-96. PubMed ID: 17966060
[TBL] [Abstract][Full Text] [Related]
54. A novel pure SERM achieves complete regression of the majority of human breast cancer tumors in nude mice.
Roy J; Couillard S; Gutman M; Labrie F
Breast Cancer Res Treat; 2003 Oct; 81(3):223-9. PubMed ID: 14620917
[TBL] [Abstract][Full Text] [Related]
55. Effects of exemestane and tamoxifen in a postmenopausal breast cancer model.
Jelovac D; Macedo L; Handratta V; Long BJ; Goloubeva OG; Ingle JN; Brodie AM
Clin Cancer Res; 2004 Nov; 10(21):7375-81. PubMed ID: 15534114
[TBL] [Abstract][Full Text] [Related]
56. Blockade of the stimulatory effect of estrogens, OH-tamoxifen, OH-toremifene, droloxifene, and raloxifene on alkaline phosphatase activity by the antiestrogen EM-800 in human endometrial adenocarcinoma Ishikawa cells.
Simard J; Sanchez R; Poirier D; Gauthier S; Singh SM; Merand Y; Belanger A; Labrie C; Labrie F
Cancer Res; 1997 Aug; 57(16):3494-7. PubMed ID: 9270018
[TBL] [Abstract][Full Text] [Related]
57. The interaction of raloxifene and the active metabolite of the antiestrogen EM-800 (SC 5705) with the human estrogen receptor.
Schafer JI; Liu H; Tonetti DA; Jordan VC
Cancer Res; 1999 Sep; 59(17):4308-13. PubMed ID: 10485477
[TBL] [Abstract][Full Text] [Related]
58. An antiangiogenic urokinase-derived peptide combined with tamoxifen decreases tumor growth and metastasis in a syngeneic model of breast cancer.
Guo Y; Mazar AP; Lebrun JJ; Rabbani SA
Cancer Res; 2002 Aug; 62(16):4678-84. PubMed ID: 12183425
[TBL] [Abstract][Full Text] [Related]
59. [Experimental study of the anti-tumor effect of arsenic trioxide or thalidomide alone and combination of both for treatment of myelodysplastic syndrome model].
Lu J; Jin J; Xu WL
Zhonghua Er Ke Za Zhi; 2006 Mar; 44(3):228-33. PubMed ID: 16624066
[TBL] [Abstract][Full Text] [Related]
60. Potent combination therapy for human breast tumors with high doses of 5-fluorouracil: remission and lack of host toxicity.
Al Safarjalani ON; Rais R; Naguib FN; el Kouni MH
Cancer Chemother Pharmacol; 2012 Jun; 69(6):1449-55. PubMed ID: 22373605
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
